Early stage drug development is full of uncertainty. Scientific risk, regulatory risk, manufacturing risk, nonclinical risk, clinical risk — each one can derail a programme long before it reaches patients. Yet many startups still approach due diligence as if it were a procedural hurdle: a checklist to complete once investors show interest.
In reality, due diligence is not a formality. It is risk intelligence — the disciplined process of identifying, understanding, and contextualising the risks that determine whether a programme is investable, technically viable, and capable of reaching the next milestone. For founders navigating today’s increasingly selective investment landscape, treating due diligence as a strategic capability rather than an administrative task can be the difference between securing funding and stalling out.
Investors Are More Selective Than Ever
The fundraising environment has shifted dramatically. Investors are no longer swayed by a compelling mechanism of action alone. They are sophisticated, scientifically literate, and acutely aware of the risks inherent in drug development. When two programmes appear equally promising, they will choose the one based on a risk profile — the one that demonstrates a clear understanding of its risks and a credible plan to manage them.
This is why due diligence has become a competitive advantage. A startup that can articulate its development plan, justify its decisions, and address its gaps transparently signals maturity, preparedness, and technical robustness. A startup that cannot, faces the possibility being dismissed before the conversation even begins.
Risk Intelligence: Seeing What Others Miss
Risk intelligence goes beyond listing potential issues. It requires the ability to:
- Identify the scientific, nonclinical, clinical, CMC, regulatory, and operational risks embedded in a programme
- Assess their severity, likelihood, and impact on timelines and cost
- Contextualise them against industry standards, competitor strategies, and regulatory expectations
- Communicate them clearly and confidently to investors
This is where many early stage teams struggle. Academic founders may understand their biology deeply, but often lack experience in CMC development, dose selection, regulatory strategy, or (non)clinical planning. Lean biotech teams may not have the internal expertise to anticipate the questions investors will ask. And because “you don’t know what you don’t know,” critical gaps often remain hidden until it’s too late.
Investors notice these gaps immediately. They are not asking naïve questions — they know exactly what they are looking for — and they expect founders to demonstrate the same level of clarity.
The Key Items That Investors Scrutinize Closely and Other Observations
Across dozens of technical due diligence engagements, certain patterns appear time and again:
- Immature CMC package that cannot support the next clinical phase
- Unjustified dose selection, often based on incomplete preclinical-to-clinical translation
- Inadequate safety narratives, especially when animal findings may translate to humans
- Unrealistic timelines, particularly when early shortcuts (e.g., accelerated Australian Phase I entry) create downstream rework
- Poorly structured data rooms, which signal disorganisation and undermine investor confidence
- Lack of internal expertise, leaving investors unsure whether the team can execute
These issues are rarely fatal on their own — but when they appear together, they erode trust. And trust is the currency of fundraising.
Mock Due Diligence: The Startup’s Secret Weapon
One of the most effective ways to build risk intelligence is through mock due diligence, also known as gap analysis. This simulated project review allows founders to uncover red flags early, understand what “real” due diligence demands are, and develop solutions before investors scrutinise the programme.
Mock due diligence does not guarantee a term sheet — but it dramatically increases the likelihood of success. It gives founders the opportunity to:
- Fix issues before they become deal breakers
- Strengthen their development plan
- Build a credible narrative
- Prepare for investor questions
- Demonstrate transparency and readiness
In short, it allows startups to control the story rather than react to it.
A Strategic Imperative, Not an Administrative Task
Due diligence is not something to prepare for once fundraising begins. It should be embedded into the programme from the start. A well-prepared startup:
- Knows its risks
- Understands its gaps
- Has a plan to address them
- Communicates with clarity and confidence
- Builds trust with investors
- Moves faster than competitors
In a landscape in which capital is scarce and investors are increasingly selective, due diligence becomes more than a requirement — it becomes a strategic differentiator.
Startups that embrace due diligence as risk intelligence position themselves to move quickly, attract investment, and build the foundations for long-term success. Those who treat it as a checkbox will find themselves outpaced by teams who understand that in drug development, clarity is power.
Author
This article has been authored by the hVIVO Drug Development Team
